Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.PMID:38421601 | DOI:10.46883/2024.25921013 (Source: Oncology (Williston Park, N.Y.))
Source: Oncology (Williston Park, N.Y.) - February 29, 2024 Category: Cancer & Oncology Authors: Lymphoma Research Foundation Lymphoma Research Foundation Source Type: research
Cancers, Vol. 16, Pages 968: Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma
ela Irga-Jaworska
Jadwiga Węcławek-Tompol
Krzysztof Kałwak
Małgorzata Sawicka-Żukowska
Maryna Krawczuk-Rybak
Anna Raciborska
Agnieszka Mizia-Malarz
Agata Sobocińska-Mirska
Paweł Łaguna
Walentyna Balwierz
Jan Styczyński
Background/aim: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment of childhood cancers is still evolving. The aim of this nationwide retrospective study was to assess the safety and effectiveness of ICIs used in a group of 42 patients, with a median age of 13.6 years, with various types of advanced malignancies treated in pediatric oncology centers in...
Source: Cancers - February 28, 2024 Category: Cancer & Oncology Authors: Agata Marja ńska Katarzyna Pawi ńska-Wąsikowska Aleksandra Wieczorek Monika Drogosiewicz Bo żenna Dembowska-Bagińska Katarzyna Bobeff Wojciech M łynarski Katarzyna Adamczewska-Wawrzynowicz Jacek Wachowiak Ma łgorzata A. Krawczyk Ninela Irga-Jaworsk Tags: Article Source Type: research
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kdelta inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study
This study evaluated the cardiac safety of parsaclisib as monotherapy based on data from 72 patients enrolled in the CITADEL-101 study. Time-matched pharmacokinetic and ECG measurements were collected at specified times for 69 patients receiving monotherapy in doses of 5, 10, 15, 20, 30, and 45 mg once daily. Based on the categorical outlier analysis, no dose-dependent effect was observed on the incidence of outliers in QT interval corrected for heart rate (HR) by Fridericia's method (QTcF), HR, or cardiac conduction. Based on central tendency analysis, the least square means (LSMs) (90% confidence interval [CI]) of ΔQTcF...
Source: Cell Research - February 26, 2024 Category: Cytology Authors: Jia Li Xiaohua Gong Xing Liu Xiang Liu Ke Szeto Xuejun Chen Source Type: research
Rare Co-occurrence of Spinal Cord Hemorrhage from Radiation-induced Cavernous Hemangioma and Classical Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
Intern Med. 2024 Feb 26. doi: 10.2169/internalmedicine.2898-23. Online ahead of print.ABSTRACTPost-transplant lymphoproliferative disorders (PTLDs) are lymphoproliferative diseases that occur after solid organ transplantation or hematopoietic stem cell transplantation (HSCT). The development of PTLD is often associated with reactivation of Epstein-Barr virus (EBV). A 26-year-old woman with a history of HSCT and total-body irradiation developed spinal cord hemorrhage from a radiation-induced cavernous hemangioma (RICH) shortly after the development of classical Hodgkin lymphoma PTLD with EBV reactivation. Although little is...
Source: Internal Medicine - February 25, 2024 Category: Internal Medicine Authors: Takahiro Shimizu Yu Nagashima Takashi Matsukawa Akihiko Mitsutake Mizuho Kawai Yurino Horiuchi Keishi Yokoyama Kensuke Takaoka Yuya Kurihara Kazuhiro Toyama Kaori Sakuishi Mineo Kurokawa Tatsushi Toda Source Type: research
